The use of monotherapy in patients with epilepsy: An appraisal of the new antiepileptic drugs
Tóm tắt
The use of antiepileptic drugs (AEDs) in monotherapy is always preferred to a polytherapy regimen because monotherapy facilitates drug compliance, is associated with a lower risk of toxicity, and is less costly. In addition, the yield of polytherapy to render a patient seizure-free when monotherapy regimens did not is relatively low. The available data derived from randomized controlled trials suggest that standard and new AEDs appear to display comparable antiepileptic efficacy but they differ with respect to tolerability and toxicity, which may be related to their pharmacodynamic and pharmacokinetic properties. New AEDs appear to be better tolerated than standard AEDs and to have fewer pharmacokinetic interactions than standard AEDs. In this article, we review the advantages of using AEDs in monotherapy in patients with newly diagnosed and refractory epilepsies, focusing on the individual properties of the drugs that may make them more appropriate in various patient groups.
Tài liệu tham khảo
Weaver LC, Swinyard EA, Woodbury LA, Goodman LS: Studies on anticonvulsant drug combinations: phenobarbital and diphenylhydantoin. J Pharmacol Exp Ther 1955, 113:359–370.
Leppik IE, Sherwin AL: Anticonvulsant activity of phenobarbital and phenytoin in combination. J Pharmacol Exp Ther 1977, 200:570–576.
Mattson RH, Cramer JA, Collins JF, et al.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985, 313:145–151.
Gilliam F, Kuzniecky R, Faught E, et al.: Patient-validated content of epilepsy-specific quality-of-life measurement. Epilepsia 1997, 38:233–236.
Mattson RH, Cramer JA, Collins JF: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992, 327:765–771.
Heller AJ, Chesterman P, Elwes RD, et al.: Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995, 58:44–50.
Shimada T, Yamazaki H, Mimura M, et al.: Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with the microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994, 270:414–423.
Pelkonen O, Maenpaa J, Taavitsainen P, et al.: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998, 28:1203–1253.
Relling MV, Pui C, Sandlund J, et al.: Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000, 356:285–290.
Villikka K, Kivisto KT, Maenpaa MD, et al.: Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharm Ther 1999, 66:589–593.
Gidal BE, Sheth RD: Epilepsy and bone health: Is there a cause for concern? Epilepsy Behav 2004, 5(Suppl 2):1–2.
Chadwick DW, Anhut H, Greiner MJ, et al.: A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945–77. Neurology 1998, 51:1282–1288.
Brodie MJ, Richens A, Yuen AW: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995, 345:476–479.
Brodie MJ, Overstall PW, Giorgi L: Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999, 37:81–87.
Steiner TJ, Dellaportas CL, Findley LJ, et al.: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999, 40:601–607.
Gilliam FG, Veloso F, Bomhof MA, et al.; Topiramate EPMN 104 Study Group: A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003, 60:196–201.
Privitera MD, Brodie MJ, Mattson RH, et al.: Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003, 107:165–175.
Bill PA, Vigonius U, Pohlmann H, et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997, 27:195–204.
Guerreiro MM, Vigonius U, Pohlmann H, et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997, 27:205–213.
Christe W, Kramer G, Vigonius U, et al.: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997, 26:451–460.
Dam M, Ekberg R, Loyning Y, et al.: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989, 3:70–76.
Ramsey E, et al.: Neurology 2005, In press.
Frank LM, Enlow T, Holmes GL, et al.: Lamictal (lamotrigine) monotherapy for typical absence seizure in children. Epilepsia 1999, 40:973–979.
Meador KJ, Loring DW, Allen ME, et al.: Comparative of carbamazepine and phenytoin in healthy adults. Neurology 1991, 41:1537–1540.
Meador KJ, Loring DW, Abney OL, et al.: Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993, 34:153–157.
Meador KJ, Loring DW, Moore EE, et al.: Comparative cognitive effects of carbamazepine and phenytoin, and valproate in healthy adults. Neurology 1995, 45:1494–1499.
Meador KJ, Loring DW, Ray PG, et al.: Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999, 40:1979–1985.
Meador KJ, Loring DW, Ray PG, et al.: Differential cognitive effects of carbamazepine and lamotrigine. Neurology 2001, 56:1177–1182.
Martin R, Kuzniecky R, Ho S, et al.: Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 1999, 52:321–327.
Bowden CL, Calabrese JR, Sachs G, et al., for the Lamictal 606 Study Group: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003, 60:392–400.
Calabrese JR, Bowden CL, Sachs G, et al., for the Lamictal 605 study group: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003, 64:1013–1024.
Pande AC, Davidson JT, Jefferson JW, et al.: Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999, 19:341–348.
Rowbotham M, Harden N, Stacey B, et al.: Gabapentin for the treatment of postherpetic neuralgia. JAMA 1998, 280:1837–1842.
Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998, 280:1831–1836.
Zvartau-Hind M, Din MU, Gilani A, et al.: Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000, 55:1587–1588. Small, uncontrolled trial that nonetheless suggests that topiramate may join the list of anticonvulsants effective for neuropathic pain.
Simpson DM, Olney R, McArthur JC, et al.: A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000, 54:2115–2119.
Storey JR, Calder CS, Hart DE, Potter DL: Topiramate in migraine prevention: a double-blind, placebo-controlled trial. Headache 2001, 41:968–975.
Kanner AM, Balabanov A: Depression in epilepsy: how closely related are these two disorders? Neurology, 2002, 58(Suppl 5):S27-S39.
Bergey GK, Morris HH, Rosenfeld W, et al.: Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. Neurology 1997, 49:739–745.
Beydoun A, Fischer J, Labar DR, et al.: Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997, 49:746–752.
Schapel GJ, Beran RG, Vajda FJ, et al.: Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993, 56:448–453.
Kanner AM, Frey M: Adding valproate to lamotrigine: a new aspect of their pharmacokinetic interaction. Neurology 2000, 55:588–591.
Sachdeo RC, Reife RA, Lim P, Pledger G: Topiramate monotherapy for partial onset seizures. Epilepsia 1997, 38:294–300.
Schachter SC, Vazquez B, Fisher RS, et al.: Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999, 52:732–737.
Beydoun A, Sachdeo RC, Rosenfeld WE, et al.: Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000, 54:2245–2251.
Sachdeo R, Beydoun A, Schachter S, et al.: Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001, 57:864–871.